1. Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial 
Peter Bytzer, Stuart J. Connolly, Sean Yang, Michael Ezekowitz, Stephan Formella, Paul A. Reilly, James Aisenberg 
Clinical Gastroenterology and Hepatology 
Volume 11, Issue 3, Pages e5 (March 2013)
DOI: /j.cgh
Copyright © 2013 AGA Institute Terms and Conditions

2. Figure 1
The time from dabigatran initiation to permanent study drug discontinuation owing to UGI AEs in RE-LY.
Clinical Gastroenterology and Hepatology  , e5DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

3. Figure 2
The relationship between UGI AEs and GI bleeding in patients taking (A) dabigatran or (B) warfarin in RE-LY.
Clinical Gastroenterology and Hepatology  , e5DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

4. Figure 3
The time from dabigatran initiation to major GI bleeding in RE-LY.
Clinical Gastroenterology and Hepatology  , e5DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions